The Motley Fool··James BrumleyImmunityBio Surges 11% on First Asian Approval for Bladder Cancer Drug
ImmunityBio stock surged 11.2% after Macau approved its bladder cancer drug Anktiva, marking the company's first Asian regulatory victory and potential gateway for regional expansion.
IBRXAsia-Pacific expansionbladder cancer